UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 31,298 Shares of United Therapeutics Co. (NASDAQ:UTHR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 12.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 212,657 shares of the biotechnology company’s stock after selling 31,298 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in United Therapeutics were worth $76,206,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Renaissance Technologies LLC grew its position in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after buying an additional 22,978 shares during the period. FMR LLC grew its holdings in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the period. LSV Asset Management grew its holdings in United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Dimensional Fund Advisors LP raised its holdings in United Therapeutics by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after purchasing an additional 22,683 shares during the period. Finally, Pacer Advisors Inc. boosted its position in shares of United Therapeutics by 0.9% during the third quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after purchasing an additional 4,869 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on UTHR shares. HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Jefferies Financial Group upped their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $370.86.

Insider Buying and Selling

In related news, CFO James Edgemond sold 7,802 shares of United Therapeutics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the transaction, the chief financial officer now owns 3,210 shares in the company, valued at approximately $1,108,766.10. This trade represents a 70.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 119,442 shares of company stock worth $44,577,770. Insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $370.12 on Tuesday. The business has a 50-day moving average of $367.77 and a 200-day moving average of $336.09. The stock has a market capitalization of $16.53 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. The business’s revenue was up 22.9% compared to the same quarter last year. On average, sell-side analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.